{
    "nctId": "NCT00319748",
    "officialTitle": "Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers",
    "inclusionCriteria": "* Adequate performance status:\n\n  * Breast - Karnofsky score \\> 50;\n  * Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score \u22642\n* If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation.\n* Normal organ function within 14 days of study entry\n* Diagnosis of one of the following malignancies:\n\n  * Metastatic breast cancer (BR)\n  * Metastatic ovarian cancer (OV)\n  * Metastatic endometrial cancer (EM)\n  * Metastatic cervical cancer (CX)\n\nBreast Cancer Inclusion Criteria:\n\n* Measurable metastatic disease (\\>1cm) in at least one site other than bone-only\n* Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease\n* Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen.\n\nOvarian Cancer Inclusion Criteria:\n\n* Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)\n* Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma).\n* Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens.\n\nEndometrial Cancer Inclusion Criteria:\n\n* Measurable metastatic disease\n* Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens\n\nCervical Cancer Inclusion Criteria:\n\n* Measurable metastatic disease\n* Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Had/have the following prior/concurrent therapy:\n\n  * Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed)\n  * Investigational drugs/agents within 14 days of first dose of 852A\n  * Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)\n  * Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions\n  * Radiotherapy within 3 weeks of the first dose of 852A\n  * Hematopoietic cell transplantation within 4 weeks of first dose of 852A\n  * Evidence of active infection within 3 days of first dose of 852A\n  * Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable)\n  * Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication\n  * History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk\n  * Uncontrolled intercurrent or chronic illness\n  * Active autoimmune disease requiring immunosuppressive therapy within 30 days\n  * Active coagulation disorder not controlled with medication\n  * Pregnant or lactating\n  * Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated\n  * Any history of brain metastases or any other active central nervous system (CNS) disease"
}